Copyright
©The Author(s) 2023.
World J Clin Cases. Nov 6, 2023; 11(31): 7619-7628
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7619
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7619
Variables | Sevoflurane group | Propofol group | P value |
Age (yr) | 70.3 ± 4.2 | 69.8 ± 3.9 | 0.54 |
Sex (male/female) | 28/32 | 26/34 | 0.72 |
BMI (kg/m2) | 24.5 ± 2.8 | 25.1 ± 3.1 | 0.31 |
ASA class (I/II/III) | 0/36/24 | 0/38/22 | 0.81 |
COPD stage (II/III/IV) | 24/28/8 | 22/30/8 | 0.83 |
Smoking history (pack-years) | 18.6 ± 6.4 | 19.2 ± 7.1 | 0.62 |
Preoperative FEV1 (% predicted) | 58.7 ± 12.3 | 59.4 ± 11.9 | 0.74 |
Preoperative FVC (% predicted) | 65.2 ± 13.6 | 66.1 ± 12.8 | 0.67 |
Preoperative PEF (% predicted) | 54.3 ± 10.9 | 55.2 ± 11.2 | 0.59 |
Primary site of BTC (ICC/ECC/GBC) | 32/16/12 | 34/14/12 | 0.86 |
Tumor stage (I/II/III/IV) | 12/24/20/4 | 14/22/18/6 | 0.79 |
Type of hepatectomy (minor/major) | 36/24 | 38/22 | 0.81 |
Bile duct resection (yes/no) | 20/40 | 18/42 | 0.72 |
Surgical duration (min) | 165 ± 35 | 170 ± 40 | 0.42 |
Intraoperative blood loss (mL) | 420 ± 180 | 430 ± 190 | 0.68 |
Intraoperative transfusion (yes/no) | 16/44 | 14/46 | 0.74 |
Variables | Sevoflurane group | Propofol group | P value |
PPCs (yes/no) | 6/54 | 15/45 | 0.02 |
Type of PPCs (n) | |||
Pneumonia | 2 | 4 | 0.67 |
Atelectasis | 3 | 9 | 0.14 |
Respiratory failure | 1 | 2 | 1.00 |
Bronchospasm | 0 | 1 | 1.00 |
Pleural effusion | 0 | 1 | 1.00 |
Severity of PPCs (n) | |||
Grade I | 3 | 7 | 0.32 |
Grade II | 2 | 7 | 0.14 |
Grade III | 1 | 1 | > 0.991 |
FEV1 (% predicted) | |||
Preoperatively | 58.7 ± 12.3 | 58.4 ± 11.9 | 0.74 |
24 h postoperatively | 52.3 ± 11.7 | 48.2 ± 10.8 | 0.03 |
48 h postoperatively | 54.6 ± 12.1 | 50.1 ± 11.2 | 0.02 |
FVC (% predicted) | |||
Preoperatively | 65.2 ± 13.6 | 66.1 ± 12.8 | 0.67 |
24 h postoperatively | 59.4 ± 13.2 | 54.8 ± 12.4 | 0.01 |
48 h postoperatively | 61.7 ± 13.5 | 56.3 ± 12.7 | 0.01 |
PEF (% predicted) | |||
Preoperatively | 54.3 ± 10.9 | 55.2 ± 11.2 | 0.59 |
24 h postoperatively | 49.5 ± 10.7 | 45.6 ± 10.3 | 0.02 |
48 h postoperatively | 51.8 ± 11.1 | 47.4 ± 10.6 | 0.01 |
IL-6 (pg/mL) | |||
Preoperatively | 15.4 ± 4.2 | 15.6 ± 4.5 | 0.81 |
24 h postoperatively | 25.2 ± 6.3 | 30.8 ± 7.1 | < 0.01 |
TNF-α (pg/mL) | |||
Preoperatively | 8.6 ± 2.1 | 8.7 ± 2.3 | 0.88 |
24 h postoperatively | 12.4 ± 3.2 | 15.6 ± 3.7 | < 0.01 |
MDA (nmol/mL) | |||
Preoperatively | 1.8 ± 0.5 | 1.9 ± 0.6 | 0.62 |
24 h postoperatively | 2.6 ± 0.7 | 3.2 ± 0.8 | < 0.01 |
8-OHdG (ng/mL) | |||
Preoperatively | 5.4 ± 1.2 | 5.6 ± 1.3 | 0.74 |
24 h postoperatively | 7.2 ± 1.6 | 8.8 ± 1.9 | < 0.01 |
VAS at rest (0-10) | |||
6 h postoperatively | 2.4 ± 1.1 | 3.2 ± 1.3 | < 0.01 |
12 h postoperatively | 2.1 ± 1.0 | 2.9 ± 1.2 | < 0.01 |
24 h postoperatively | 1.8 ± 0.9 | 2.6 ± 1.1 | < 0.01 |
VAS during movement (0-10) | |||
6 h postoperatively | 4.2 ± 1.4 | 5.4 ± 1.6 | < 0.01 |
12 h postoperatively | 3.8 ± 1.3 | 5.0 ± 1.5 | < 0.01 |
24 h postoperatively | 3.4 ± 1.2 | 4.6 ± 1.4 | < 0.01 |
Length of hospital stay (d) | 12 (10-14) | 18 (15-21) | < 0.011 |
Morbidity (yes/no) | 8/52 | 18/42 | < 0.011 |
Mortality (yes/no) | 2/58 | 3/57 | > 0.991 |
Recurrence-free survival (mo) | |||
Median | 18 | 19 | 0.38 |
95%CI | 15-21 | 16-22 | |
Overall survival (mo) | |||
Median | 24 | 25 | 0.46 |
95%CI | 21-27 | 22-28 |
- Citation: Yao Y, Zhang MS, Li YB, Zhang MZ. Protective effect of sevoflurane on lung function of elderly chronic obstructive pulmonary disease patients undergoing total hip arthroplasty. World J Clin Cases 2023; 11(31): 7619-7628
- URL: https://www.wjgnet.com/2307-8960/full/v11/i31/7619.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i31.7619